Lexicon Pharmaceuticals PE Ratio 2006-2021 | LXRX

Current and historical p/e ratio for Lexicon Pharmaceuticals (LXRX) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Lexicon Pharmaceuticals PE ratio as of October 22, 2021 is 13.42.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Lexicon Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 5.10 13.08
2021-06-30 4.59 $0.39 11.77
2021-03-31 5.87 $-0.13 0.00
2020-12-31 3.42 $-0.61 0.00
2020-09-30 1.44 $-1.05 0.00
2020-06-30 2.00 $0.19 10.50
2020-03-31 1.95 $0.62 3.15
2019-12-31 4.15 $1.04 3.99
2019-09-30 3.01 $1.36 2.21
2019-06-30 6.29 $-0.85 0.00
2019-03-31 5.56 $-0.96 0.00
2018-12-31 6.64 $-1.15 0.00
2018-09-30 10.67 $-1.26 0.00
2018-06-30 12.00 $-1.29 0.00
2018-03-31 8.57 $-1.29 0.00
2017-12-31 9.88 $-1.22 0.00
2017-09-30 12.29 $-1.26 0.00
2017-06-30 16.45 $-1.32 0.00
2017-03-31 14.34 $-1.36 0.00
2016-12-31 13.83 $-1.37 0.00
2016-09-30 18.07 $-0.30 0.00
2016-06-30 14.35 $-0.29 0.00
2016-03-31 11.95 $-0.19 0.00
2015-12-31 13.31 $-0.13 0.00
2015-09-30 10.74 $-0.89 0.00
2015-06-30 8.05 $-1.11 0.00
2015-03-31 6.61 $-1.19 0.00
2014-12-31 6.37 $-1.33 0.00
2014-09-30 9.87 $-1.54 0.00
2014-06-30 11.27 $-1.40 0.00
2014-03-31 12.11 $-1.47 0.00
2013-12-31 12.59 $-1.40 0.00
2013-09-30 16.66 $-1.54 0.00
2013-06-30 15.19 $-1.54 0.00
2013-03-31 15.26 $-1.47 0.00
2012-12-31 15.47 $-1.54 0.00
2012-09-30 16.24 $-1.89 0.00
2012-06-30 15.72 $-2.03 0.00
2012-03-31 13.02 $-2.24 0.00
2011-12-31 9.03 $-2.45 0.00
2011-09-30 6.44 $-2.24 0.00
2011-06-30 12.32 $-2.24 0.00
2011-03-31 11.76 $-2.17 0.00
2010-12-31 10.08 $-2.45 0.00
2010-09-30 11.20 $-2.87 0.00
2010-06-30 8.96 $-3.29 0.00
2010-03-31 10.43 $-3.85 0.00
2009-12-31 11.90 $-4.06 0.00
2009-09-30 14.91 $-3.92 0.00
2009-06-30 8.68 $-4.13 0.00
2009-03-31 7.63 $-4.13 0.00
2008-12-31 9.80 $-3.92 0.00
2008-09-30 12.46 $-3.78 0.00
2008-06-30 11.20 $-3.57 0.00
2008-03-31 14.14 $-3.71 0.00
2007-12-31 21.21 $-4.48 0.00
2007-09-30 24.22 $-5.18 0.00
2007-06-30 22.47 $-5.60 0.00
2007-03-31 25.41 $-6.23 0.00
2006-12-31 25.27 $-5.74 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.737B $0.024B
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomictechnologies to accelerate large-scale analysis of mammalian gene function for drug discovery.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76